MCID: SPP011
MIFTS: 61

Suppression of Tumorigenicity 12

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Suppression of Tumorigenicity 12

MalaCards integrated aliases for Suppression of Tumorigenicity 12:

Name: Suppression of Tumorigenicity 12 57
Prostate Adenocarcinoma 57 12 13 15
Adenocarcinoma of Prostate 6 73
Prostate Adenocarcinoma 1; Pac1 57
Prostate Adenocarcinoma 1 57
St12 57
Pac1 57

Classifications:



External Ids:

OMIM 57 601188
Disease Ontology 12 DOID:2526
NCIt 50 C2919
SNOMED-CT 68 399490008
UMLS 73 C0007112

Summaries for Suppression of Tumorigenicity 12

Disease Ontology : 12 A prostate carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Suppression of Tumorigenicity 12, also known as prostate adenocarcinoma, is related to adenocarcinoma and lymphoepithelioma-like acinar prostate adenocarcinoma. An important gene associated with Suppression of Tumorigenicity 12 is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Focal Adhesion. The drugs Lidocaine and Prilocaine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased cell migration

Description from OMIM: 601188

Related Diseases for Suppression of Tumorigenicity 12

Diseases related to Suppression of Tumorigenicity 12 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.1 AKT1 BRAF CTNNB1 HRAS PIK3CA PTEN
2 lymphoepithelioma-like acinar prostate adenocarcinoma 12.0
3 submandibular gland cancer 11.1 KLK3 TP53
4 thyroid hurthle cell adenoma 11.1 PIK3CA PTEN
5 rare adenocarcinoma of the breast 11.1 AKT1 PIK3CA TP53
6 nevus of ota 11.1 BRAF TP53
7 adult hepatocellular carcinoma 11.1 CTNNB1 PIK3CA TP53
8 female reproductive endometrioid cancer 11.1 CTNNB1 PTEN TP53
9 spitz nevus 11.1 BRAF HRAS TP53
10 anal squamous cell carcinoma 11.1 AKT1 PIK3CA TP53
11 prostate adenoid cystic carcinoma 11.1 HRAS KLK3 PIK3CA
12 prostate transitional cell carcinoma 11.1 CTNNB1 KLK3 PIK3CA
13 gliomatosis cerebri 11.1 IDH1 PTEN TP53
14 esophagus adenocarcinoma 11.1 PIK3CA SMAD4 TP53
15 proteus syndrome 11.1 AKT1 PIK3CA PTEN
16 leopard syndrome 11.1 AKT1 BRAF HRAS
17 female urethral cancer 11.1 CHGA KLK3
18 ovarian clear cell carcinoma 11.0 PIK3CA PTEN TP53
19 biliary tract neoplasm 11.0 HRAS SMAD4 TP53
20 intracranial chondrosarcoma 11.0 IDH1 TP53
21 gastrointestinal system benign neoplasm 11.0 CTNNB1 HRAS TP53
22 bile duct adenocarcinoma 11.0 HRAS IDH1 TP53
23 intestinal benign neoplasm 11.0 CTNNB1 HRAS TP53
24 villous adenoma 11.0 BRAF FOLH1 KLK3
25 bladder squamous cell carcinoma 11.0 BRAF PIK3CA PTEN TP53
26 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 11.0 CTNNB1 PIK3CA PTEN TP53
27 skin squamous cell carcinoma 11.0 BRAF HRAS PIK3CA TP53
28 bartholin's duct cyst 11.0 AR TP53
29 apocrine adenoma 11.0 HRAS PIK3CA
30 atrophy of prostate 11.0 KLK3 TP53
31 signet ring cell adenocarcinoma 11.0 CHGA CTNNB1 TP53
32 giant cell glioblastoma 11.0 BRAF IDH1 PTEN TP53
33 integumentary system cancer 11.0 AKT1 HRAS TP53
34 brain stem glioma 11.0 BRAF IDH1 PIK3CA TP53
35 ovarian cancer 1 11.0 AKT1 HRAS PIK3CA TP53
36 malignant ovarian surface epithelial-stromal neoplasm 11.0 AKT1 HRAS PIK3CA TP53
37 endometrial adenocarcinoma 11.0 AKT1 PTEN TP53
38 prostate squamous cell carcinoma 11.0 HRAS KLK3 PIK3CA TP53
39 nodular prostate 11.0 AR FOLH1 KLK3
40 ovary epithelial cancer 11.0 AKT1 HRAS PIK3CA TP53
41 serous cystadenocarcinoma 11.0 AKT1 HRAS PIK3CA TP53
42 urethra adenocarcinoma 11.0 AMACR KLK3 SMAD4
43 estrogen-receptor positive breast cancer 11.0 AKT1 PIK3CA TP53
44 urethra clear cell adenocarcinoma 11.0 AMACR KLK3 SMAD4
45 ovarian serous cystadenocarcinoma 11.0 BRAF HRAS PIK3CA TP53
46 ganglioglioma 11.0 BRAF CHGA TP53
47 lung benign neoplasm 11.0 CHGA HRAS TP53
48 cystadenocarcinoma 11.0 AKT1 HRAS PIK3CA TP53
49 cystitis cystica 11.0 AR CTNNB1 KLK3
50 cerebellar astrocytoma 11.0 IDH1 TP53

Graphical network of the top 20 diseases related to Suppression of Tumorigenicity 12:



Diseases related to Suppression of Tumorigenicity 12

Symptoms & Phenotypes for Suppression of Tumorigenicity 12

Clinical features from OMIM:

601188

GenomeRNAi Phenotypes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.93 PIK3CA PTEN SLC45A3 SMAD4 TMPRSS2 TP53
2 Decreased cell migration GR00055-A-1 9.72 PIK3CA AKT1 BRAF CTNNB1 HRAS
3 Increased cell death HMECs cells GR00103-A-0 9.43 KLK3 PIK3CA PTEN TP53 CTNNB1 GSTP1
4 Decreased sensitivity to paclitaxel GR00112-A-0 9.26 PTEN SMAD4
5 Increased cell migration GR00055-A-3 8.92 PIK3CA BRAF CTNNB1 HRAS

MGI Mouse Phenotypes related to Suppression of Tumorigenicity 12:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 BRAF CTNNB1 AMACR IDH1 AR AKT1
2 growth/size/body region MP:0005378 10.38 BRAF CTNNB1 AMACR IDH1 AR AKT1
3 mortality/aging MP:0010768 10.38 BRAF CTNNB1 AMACR IDH1 AR KLF6
4 endocrine/exocrine gland MP:0005379 10.36 AR KLF6 AKT1 CHGA HRAS BRAF
5 behavior/neurological MP:0005386 10.33 AKT1 HRAS CTNNB1 BRAF AR SMAD4
6 cardiovascular system MP:0005385 10.32 BRAF CTNNB1 AR CHGA AKT1 HRAS
7 cellular MP:0005384 10.32 AKT1 CTNNB1 BRAF AR SMAD4 SRRM4
8 embryo MP:0005380 10.3 BRAF CTNNB1 AR KLF6 AKT1 TMPRSS2
9 integument MP:0010771 10.21 BRAF CTNNB1 AR AKT1 HRAS SMAD4
10 digestive/alimentary MP:0005381 10.17 HRAS CTNNB1 BRAF AR TP53 SMAD4
11 neoplasm MP:0002006 10.17 AR AKT1 HRAS BRAF CTNNB1 TMPRSS2
12 liver/biliary system MP:0005370 10.15 AMACR BRAF CTNNB1 AR AKT1 SMAD4
13 adipose tissue MP:0005375 10.14 AMACR BRAF AR AKT1 TP53 PTEN
14 muscle MP:0005369 10.06 CTNNB1 BRAF AR AKT1 SMAD4 TP53
15 normal MP:0002873 10.02 HRAS CTNNB1 BRAF AR AKT1 SMAD4
16 no phenotypic analysis MP:0003012 9.95 HRAS CTNNB1 CHGA SRRM4 TP53 PIK3CA
17 reproductive system MP:0005389 9.93 BRAF CTNNB1 AR KLF6 AKT1 CHGA
18 renal/urinary system MP:0005367 9.86 BRAF CTNNB1 AR CHGA HRAS TP53
19 pigmentation MP:0001186 9.72 CTNNB1 BRAF AR TP53 PTEN
20 respiratory system MP:0005388 9.61 IDH1 BRAF CTNNB1 AKT1 HRAS TP53
21 skeleton MP:0005390 9.36 BRAF CTNNB1 IDH1 AR AKT1 HRAS

Drugs & Therapeutics for Suppression of Tumorigenicity 12

Drugs for Suppression of Tumorigenicity 12 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 391)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Prilocaine Approved Phase 4 721-50-6 4906
3
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
6 Anesthetics, Local Phase 4,Phase 2
7 Anti-Arrhythmia Agents Phase 4
8 Central Nervous System Depressants Phase 4
9 Diuretics, Potassium Sparing Phase 4,Not Applicable
10 Sodium Channel Blockers Phase 4,Not Applicable
11 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
12 Cholinergic Agents Phase 4
13 Cholinergic Antagonists Phase 4
14 Muscarinic Antagonists Phase 4
15
Bicalutamide Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 90357-06-5 56069 2375
16
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
17
Cyproterone Acetate Approved, Investigational Phase 3 427-51-0
18
Goserelin Approved Phase 3,Phase 2,Phase 1,Not Applicable 65807-02-5 47725 5311128
19
Flutamide Approved, Investigational Phase 3,Phase 2,Phase 1 13311-84-7 3397
20
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
21
Estramustine Approved, Investigational Phase 3,Phase 1,Phase 2 2998-57-4 18140 259331
22
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
23
Testosterone Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0 6013
24
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
25
Prednisone Approved, Vet_approved Phase 3,Phase 1,Phase 2 53-03-2 5865
26
Mitoxantrone Approved, Investigational Phase 3,Phase 1,Phase 2 65271-80-9 4212
27
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
28
Methyltestosterone Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
29
Testosterone enanthate Approved Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
30
Testosterone undecanoate Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
31
Leuprolide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 53714-56-0 3911 657181
32
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
33
Norepinephrine Approved Phase 3 51-41-2 439260
34
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-23-7 5754
35
Ketoconazole Approved, Investigational Phase 3,Phase 2,Phase 1 65277-42-1 47576 3823
36
Nilutamide Approved, Investigational Phase 3,Phase 2,Phase 1 63612-50-0 4493
37
Vinblastine Approved Phase 3,Phase 1,Phase 2 865-21-4 13342 241903
38
Buserelin Approved, Investigational Phase 3,Phase 2,Phase 1 57982-77-1
39
Glycolic acid Approved, Investigational Phase 3 79-14-1 757
40
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
41
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
42
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
43
Diethylstilbestrol Approved, Investigational Phase 3 56-53-1 3054 448537
44
Suramin Approved, Investigational Phase 3 145-63-1 5361
45
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1 7553-56-2 807
46
Clodronate Approved, Investigational, Vet_approved Phase 3 10596-23-3 25419
47
Zoledronic acid Approved Phase 3,Phase 2,Phase 1 118072-93-8 68740
48
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
49
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2 50-28-2 5757
50 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Phase 2 979-32-8

Interventional clinical trials:

(show top 50) (show all 618)
# Name Status NCT ID Phase Drugs
1 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel;periprostatic nerve blockade
2 A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy Active, not recruiting NCT01661166 Phase 4 Fesoterodine
3 A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel Unknown status NCT00764166 Phase 3 Docetaxel + hormonal treatment (LH-RH agonist);Hormonal treatment (LH-RH agonist)
4 Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer Unknown status NCT00363285 Phase 3 cyproterone acetate
5 Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer Unknown status NCT00104715 Phase 3 antiandrogen therapy;docetaxel;goserelin acetate
6 Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer Unknown status NCT00392535 Phase 3 cyproterone acetate;releasing hormone agonist therapy
7 Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer Unknown status NCT00376792 Phase 3 docetaxel
8 Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer Unknown status NCT00796458 Phase 3 docetaxel;releasing hormone agonist therapy
9 Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer Unknown status NCT00084552 Phase 3
10 Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer Unknown status NCT00003734 Phase 3 flutamide;triptorelin
11 Androgen Deprivation Therapy in Treating Patients With Prostate Cancer Unknown status NCT00110162 Phase 3 antiandrogen therapy;releasing hormone agonist therapy
12 Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma Completed NCT01011751 Phase 3 Cyproterone acetate;Medroxyprogesterone acetate;Venlafaxine;Leuprorelin;Flutamide;Placebo
13 Image Guided Radiation Therapy For Prostate Cancer Completed NCT00433706 Phase 3
14 Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Completed NCT00002855 Phase 3 Bicalutamide;Doxorubicin hydrochloride;Estramustine Phosphate Sodium;Flutamide;Ketoconazole;Nilutamide;Therapeutic Hydrocortisone;Vinblastine
15 Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed NCT00002597 Phase 3 flutamide;Zoladex;Lupron
16 Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer Completed NCT00002633 Phase 3 bicalutamide;buserelin;flutamide;goserelin;leuprolide acetate;nilutamide
17 Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer Completed NCT00003607 Phase 3
18 Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy Completed NCT00065442 Phase 3
19 A Study of Leuprolide to Treat Prostate Cancer Completed NCT00626431 Phase 3 Leuprolide acetate - Formulation A;Leuprolide acetate - Formulation B
20 Radiation Therapy After Prostatectomy in Treating Patients With Stage III Prostate Cancer Completed NCT00394511 Phase 3
21 Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer Completed NCT01697384 Phase 3 histrelin acetate
22 Study of Histrelin Subdermal Implant in Patients With Prostate Cancer Completed NCT01394263 Phase 3 Histrelin hydrogel implant;Zoladex goserelin implant
23 Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer Completed NCT00182052 Phase 3 Rosiglitazone
24 Hormone Therapy in Treating Patients With Advanced Prostate Cancer Completed NCT00003026 Phase 3 bicalutamide;flutamide;triptorelin
25 Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer Completed NCT00657904 Phase 3 Bicalutamide;Placebo
26 Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer Completed NCT00002760 Phase 3 ketoconazole;therapeutic hydrocortisone
27 Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer Completed NCT00067015 Phase 3 bicalutamide;goserelin acetate
28 Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer Completed NCT00027859 Phase 3 docetaxel;estramustine phosphate sodium;ketoconazole;therapeutic hydrocortisone
29 Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer Completed NCT00003653 Phase 3 bicalutamide;buserelin;cyproterone acetate;flutamide;goserelin;leuprolide acetate;nilutamide
30 A Long Term Safety Study With Atrasentan Completed NCT00127478 Phase 2, Phase 3 Atrasentan
31 Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer Completed NCT00316927 Phase 3 acetylsalicylic acid;dexamethasone;diethylstilbestrol
32 Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer Completed NCT00255606 Phase 3 docetaxel;prednisone
33 Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer Completed NCT00002881 Phase 3 flutamide;goserelin acetate;leuprolide acetate;suramin;therapeutic hydrocortisone
34 Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Completed NCT00005947 Phase 3
35 Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer Completed NCT00023686 Phase 3
36 S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy Completed NCT00004001 Phase 3 docetaxel;estramustine;mitoxantrone;prednisone
37 SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer Completed NCT00002651 Phase 3 bicalutamide;goserelin acetate
38 Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy Completed NCT00110214 Phase 3 docetaxel;prednisone
39 Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer Completed NCT00062309 Phase 3
40 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Completed NCT00134056 Phase 3 atrasentan hydrochloride;docetaxel;prednisone
41 Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer Completed NCT00002703 Phase 3
42 Combination Chemotherapy in Treating Pain in Patients With Hormone Refractory Metastatic Prostate Cancer Completed NCT00003232 Phase 3 clodronate disodium;mitoxantrone hydrochloride;prednisone
43 Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Completed NCT00079001 Phase 3 zoledronic acid;androgen deprivation therapy;GnRH agonist
44 Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer Completed NCT00002723 Phase 3 suramin;suramin;Suramin
45 Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy Completed NCT00931528 Phase 3 Tadalafil
46 Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy Completed NCT01707966 Phase 3 Orteronel;Placebo
47 Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer Completed NCT00002511 Phase 3
48 Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer Completed NCT00769548 Phase 3 flutamide;goserelin acetate
49 Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer Completed NCT00423475 Phase 3 goserelin acetate
50 Atrasentan in Treating Patients With Prostate Cancer Completed NCT00046943 Phase 3 atrasentan hydrochloride

Search NIH Clinical Center for Suppression of Tumorigenicity 12

Genetic Tests for Suppression of Tumorigenicity 12

Anatomical Context for Suppression of Tumorigenicity 12

MalaCards organs/tissues related to Suppression of Tumorigenicity 12:

41
Prostate, Bone, Lymph Node, Lung, Testes, Endothelial, Bone Marrow

Publications for Suppression of Tumorigenicity 12

Articles related to Suppression of Tumorigenicity 12:

(show top 50) (show all 839)
# Title Authors Year
1
PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy. ( 28924059 )
2018
2
Prostate adenocarcinoma in a young patient with multiple endocrine neoplasia 2B. ( 29530270 )
2018
3
Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. ( 29976500 )
2018
4
Gastrointestinal Bleeding from Metastatic Prostate Adenocarcinoma to the Stomach. ( 28377935 )
2017
5
An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography (18)F-FLT PET/CT in Prostate Adenocarcinoma. ( 28375169 )
2017
6
Overexpression of Aquaporin-1 is a Prognostic Factor for Biochemical Recurrence in Prostate Adenocarcinoma. ( 27817002 )
2017
7
Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma. ( 28552539 )
2017
8
Risk of lymph node metastases in pathological gleason scorea8o6 prostate adenocarcinoma: Analysis of institutional and population-based databases. ( 27692833 )
2017
9
Complete biochemical response after pulmonary metastasectomy in prostate adenocarcinoma. ( 28932626 )
2017
10
The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? ( 28191651 )
2017
11
Metastatic Prostate Adenocarcinoma to the Brain: Case Reports and Literature Review. ( 28352499 )
2017
12
Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. ( 28590015 )
2017
13
Incidental Prostate Adenocarcinoma in Cystoprostatectomy Specimens: Partial Versus Complete Prostate Sampling. ( 28381150 )
2017
14
Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes. ( 28716144 )
2017
15
Endoplasmic reticulum protein ERp46 in prostate adenocarcinoma. ( 28521463 )
2017
16
Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma. ( 28107606 )
2017
17
Epididymal metastasis from prostate adenocarcinoma: An unusual and challenging diagnosis suspected in gallium-68 prostate-specific membrane antigen-positron emission tomography/computed tomography and histologically confirmed. ( 28216940 )
2017
18
Ductal variant of prostate adenocarcinoma harbor Xenotropic murine leukemia virus related virus (XMRV) infection: a novel finding in subtype of prostate cancer. ( 28861296 )
2017
19
The role of nutrition in the prevention of prostatic adenocarcinoma. ( 28952237 )
2017
20
A role of human beta defensin-1 in predicting prostatic adenocarcinoma in cases of false-negative biopsy. ( 28885732 )
2017
21
Testicular Metastasis From Prostatic Adenocarcinoma Presenting as Recurrent Epididymo-orchitis. ( 28760557 )
2017
22
Prostatic Adenocarcinoma in the Setting of Persistent MA1llerian Duct Syndrome: A Case Report. ( 29137935 )
2017
23
Incomplete cavernous sinus syndrome as the initial manifestation of a previously undetected metastatic prostate adenocarcinoma. ( 28474478 )
2017
24
Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals. ( 28230260 )
2017
25
Differentiating tumor heterogeneity in formalin-fixed paraffin-embedded (FFPE) prostate adenocarcinoma tissues using principal component analysis of matrix-assisted laser desorption/ionization imaging mass spectral data. ( 27791282 )
2017
26
Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma. ( 28888085 )
2017
27
Prostate adenocarcinoma metastases to the testis and brain: case report and review of the literature. ( 28845236 )
2017
28
Nonspecific granulomatous prostatitis in association with eosinophilic epithelial metaplasia and prostatic adenocarcinoma. ( 28937384 )
2017
29
Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. ( 28389666 )
2017
30
Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids. ( 28881646 )
2017
31
pCramoll and rCramoll lectins induce cell death in human prostate adenocarcinoma (PC-3) cells by impairment of mitochondrial homeostasis. ( 28552641 )
2017
32
Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol 2016. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.046. ( 28111115 )
2017
33
Yes-Associated Protein Expression Is Correlated to the Differentiation of Prostate Adenocarcinoma. ( 28602051 )
2017
34
Treatment-naA^ve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect. ( 28587951 )
2017
35
Renal and retroperitoneal metastasis from prostate adenocarcinoma: a case report. ( 26957001 )
2016
36
Bilaterally mammary acanthosis nigricans as paraneoplastic manifestation of prostate adenocarcinoma. ( 27595210 )
2016
37
Re: Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. ( 27567208 )
2016
38
ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma. ( 27189342 )
2016
39
Radiologic presentation of chronic granulomatous prostatitis mimicking locally advanced prostate adenocarcinoma. ( 27257455 )
2016
40
Characterization of Notch Signalling Pathway Members in Normal Prostate, Prostatic Intraepithelial Neoplasia (PIN) and Prostatic Adenocarcinoma. ( 26341090 )
2016
41
Seminal Vesicle Leiomyoma Mimicking Extra-prostatic Extension ofA Prostatic Adenocarcinoma. ( 27169020 )
2016
42
Gleason Grade 4 Prostate Adenocarcinoma Patterns: An Inter-observer Agreement Study among Genitourinary Pathologists. ( 27028587 )
2016
43
MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: a88A Comparison With AMACR. ( 27543977 )
2016
44
Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma. ( 27051534 )
2016
45
Metastasis of Prostate Adenocarcinoma to the Testis. ( 27703299 )
2016
46
Modification of the pT2 substage classification in prostate adenocarcinoma. ( 27251951 )
2016
47
Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and AbraxaneAr for treatment of human prostate adenocarcinoma in mice. ( 27297780 )
2016
48
Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria. ( 27486316 )
2016
49
mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma. ( 27096957 )
2016
50
Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. ( 27753182 )
2016

Variations for Suppression of Tumorigenicity 12

ClinVar genetic disease variations for Suppression of Tumorigenicity 12:

6
(show top 50) (show all 366)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
4 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
7 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
9 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
10 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
11 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
12 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
13 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
14 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
20 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
21 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
22 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
23 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
24 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
25 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
26 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
27 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
28 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
29 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
30 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
31 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
32 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
33 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
34 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
35 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
36 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
37 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
38 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
39 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
40 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
41 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
42 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
43 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
44 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
45 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh38 Chromosome 7, 140753345: 140753345
46 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
47 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
48 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
49 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
50 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402

Expression for Suppression of Tumorigenicity 12

Search GEO for disease gene expression data for Suppression of Tumorigenicity 12.

Pathways for Suppression of Tumorigenicity 12

Pathways related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 AKT1 CTNNB1 HRAS PIK3CA PTEN TP53
2
Show member pathways
12.97 AKT1 BRAF CTNNB1 HRAS PIK3CA PTEN
3
Show member pathways
12.86 AKT1 BRAF CTNNB1 HRAS KLK3
4
Show member pathways
12.84 AKT1 BRAF HRAS PIK3CA PTEN TP53
5
Show member pathways
12.79 AKT1 BRAF CTNNB1 HRAS PIK3CA
6
Show member pathways
12.79 AKT1 HRAS PIK3CA PTEN TP53
7
Show member pathways
12.77 AKT1 BRAF CTNNB1 HRAS PIK3CA PTEN
8
Show member pathways
12.75 AKT1 BRAF CTNNB1 GSTP1 HRAS PIK3CA
9
Show member pathways
12.73 AKT1 CTNNB1 HRAS PIK3CA PTEN
10
Show member pathways
12.66 AKT1 CTNNB1 HRAS PIK3CA TP53
11
Show member pathways
12.61 AKT1 CTNNB1 HRAS PIK3CA PTEN SMAD4
12 12.59 HRAS PIK3CA PTEN SLC45A3 TP53
13
Show member pathways
12.58 AKT1 BRAF HRAS PIK3CA PTEN TP53
14
Show member pathways
12.57 AKT1 BRAF CTNNB1 HRAS PIK3CA SMAD4
15
Show member pathways
12.55 AKT1 BRAF HRAS PIK3CA TP53
16
Show member pathways
12.52 AKT1 CTNNB1 HRAS PIK3CA TP53
17 12.49 AKT1 CTNNB1 HRAS PIK3CA SMAD4 TP53
18
Show member pathways
12.48 AKT1 HRAS PIK3CA TP53
19
Show member pathways
12.48 AKT1 BRAF CTNNB1 HRAS PIK3CA
20
Show member pathways
12.46 AKT1 BRAF HRAS PIK3CA PTEN
21 12.45 AKT1 AR BRAF CTNNB1 GSTP1 HRAS
22
Show member pathways
12.41 AKT1 AR BRAF PIK3CA
23
Show member pathways
12.39 AKT1 HRAS PIK3CA PTEN
24
Show member pathways
12.38 AKT1 CTNNB1 HRAS PIK3CA
25
Show member pathways
12.34 BRAF CTNNB1 HRAS PIK3CA
26 12.34 AKT1 BRAF CTNNB1 HRAS PIK3CA TP53
27
Show member pathways
12.28 AKT1 BRAF HRAS TP53
28 12.28 AKT1 BRAF CTNNB1 SMAD4 TP53
29 12.26 AKT1 BRAF HRAS PTEN
30
Show member pathways
12.26 AKT1 BRAF HRAS PIK3CA TP53
31 12.26 AKT1 HRAS PIK3CA PTEN TP53
32
Show member pathways
12.25 AKT1 HRAS PIK3CA PTEN
33 12.23 AKT1 HRAS PIK3CA PTEN TP53
34
Show member pathways
12.22 AKT1 BRAF HRAS TP53
35
Show member pathways
12.21 AKT1 HRAS PIK3CA PTEN
36
Show member pathways
12.21 AKT1 HRAS PIK3CA TP53
37 12.18 AKT1 CTNNB1 GSTP1 PIK3CA TP53
38
Show member pathways
12.18 AKT1 AR BRAF CTNNB1 GSTP1 HRAS
39 12.17 AKT1 CTNNB1 HRAS PIK3CA SMAD4
40 12.15 AKT1 KLF6 SMAD4 TP53
41 12.14 AKT1 BRAF HRAS PIK3CA TP53
42 12.14 AKT1 AR BRAF CTNNB1 PTEN SMAD4
43 12.13 AKT1 HRAS PIK3CA PTEN
44
Show member pathways
12.12 AKT1 HRAS PIK3CA PTEN TP53
45
Show member pathways
12.11 AKT1 BRAF PIK3CA TP53
46
Show member pathways
12.11 AKT1 BRAF CTNNB1 HRAS PIK3CA
47
Show member pathways
12.11 AKT1 BRAF HRAS PIK3CA PTEN SMAD4
48
Show member pathways
12.08 AKT1 AR CTNNB1 HRAS KLK3 PIK3CA
49 12.07 AKT1 HRAS PIK3CA PTEN TP53
50 12.06 AKT1 CTNNB1 HRAS PIK3CA TP53

GO Terms for Suppression of Tumorigenicity 12

Biological processes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 AKT1 AR CTNNB1 HRAS KLF6 NKX3-1
2 positive regulation of cell proliferation GO:0008284 9.93 AKT1 AR CTNNB1 HRAS NKX3-1 PTEN
3 negative regulation of gene expression GO:0010629 9.91 AKT1 CTNNB1 HRAS NKX3-1
4 positive regulation of transcription, DNA-templated GO:0045893 9.87 AKT1 AR CTNNB1 KLF6 NKX3-1 SMAD4
5 cellular response to insulin stimulus GO:0032869 9.81 AKT1 GSTP1 PTEN
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.8 AKT1 BRAF PIK3CA
7 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.77 GSTP1 PTEN SMAD4
8 cellular response to drug GO:0035690 9.76 BRAF NKX3-1 TP53
9 negative regulation of epithelial cell proliferation GO:0050680 9.75 AR NKX3-1 PTEN
10 epidermal growth factor receptor signaling pathway GO:0007173 9.74 AKT1 HRAS PIK3CA
11 negative regulation of neuron death GO:1901215 9.71 AKT1 CHGA CTNNB1
12 cellular response to hypoxia GO:0071456 9.71 AKT1 NKX3-1 PTEN TP53
13 androgen receptor signaling pathway GO:0030521 9.7 AR CTNNB1 NKX3-1
14 negative regulation of cell proliferation GO:0008285 9.7 AR CTNNB1 HRAS NKX3-1 PTEN SMAD4
15 cellular response to nerve growth factor stimulus GO:1990090 9.65 AKT1 BRAF PTEN
16 cellular response to steroid hormone stimulus GO:0071383 9.64 AR NKX3-1
17 seminiferous tubule development GO:0072520 9.62 AR SMAD4
18 anoikis GO:0043276 9.62 AKT1 PIK3CA
19 negative regulation of cell size GO:0045792 9.61 AKT1 PTEN
20 positive regulation of glucose metabolic process GO:0010907 9.6 AKT1 SLC45A3
21 regulation of axon regeneration GO:0048679 9.56 BRAF PTEN
22 protein kinase B signaling GO:0043491 9.56 AKT1 NKX3-1 PIK3CA PTEN
23 prostate gland growth GO:0060736 9.55 AR PTEN
24 epithelial cell differentiation involved in prostate gland development GO:0060742 9.51 AR CTNNB1
25 cell proliferation GO:0008283 9.5 AKT1 AR CTNNB1 HRAS PTEN SMAD4
26 cellular response to decreased oxygen levels GO:0036294 9.49 AKT1 PTEN
27 positive regulation of epithelial cell proliferation involved in prostate gland development GO:0060769 9.43 AR CTNNB1
28 positive regulation of gene expression GO:0010628 9.23 AKT1 AR BRAF CTNNB1 HRAS NKX3-1

Molecular functions related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.67 AR NKX3-1 SMAD4 TP53
2 protein kinase binding GO:0019901 9.65 AKT1 CTNNB1 GSTP1 PTEN TP53
3 enzyme binding GO:0019899 9.55 AKT1 AR CTNNB1 PTEN TP53
4 I-SMAD binding GO:0070411 9.32 CTNNB1 SMAD4
5 androgen receptor activity GO:0004882 8.96 AR NKX3-1
6 RNA polymerase II transcription factor binding GO:0001085 8.92 AR CTNNB1 SMAD4 TP53

Sources for Suppression of Tumorigenicity 12

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....